Hims & Hers Health, Inc. Class A Common Stock (HIMS)
40.49
-0.19 (-0.47%)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care
The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery.

These were the 20 tickers that Benzinga readers searched for the most during the month of February.
Via Benzinga · March 4, 2025

U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors.
Via Benzinga · March 4, 2025
Post earnings has seen little bullish follow-through, and this typically means the broad market won’t have much to shout about over the coming weeks.
Via Talk Markets · March 2, 2025

Via Benzinga · February 28, 2025

Via The Motley Fool · March 1, 2025

The past few weeks have brought a dramatic change in investor sentiment.
Via Talk Markets · February 28, 2025

Can Hims & Hers Health recover after the FDA removed semaglutide from its drugs shortage list?
Via Investor's Business Daily · February 28, 2025

Via Benzinga · February 27, 2025

Nvidia reported its much anticipated 4Q earnings after the close. It was a mixed bag.
Via Talk Markets · February 26, 2025

Healthcare tech company GoodRx (NASDAQGDRX)
will be announcing earnings results tomorrow before the bell. Here’s what investors should know.
Via StockStory · February 26, 2025

Via Benzinga · February 26, 2025

Hims & Hers grew 95% in the fourth quarter of 2024, but investors were worried about GLP-1 growth.
Via The Motley Fool · February 25, 2025

See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes.
Via MarketBeat · February 26, 2025

Shares of telehealth company Hims & Hers Health (NYSEHIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected, and EBITDA came in a bit short, but revenue soared year over year, easily beating Wall Street's forecasts. This jump came from surging demand in the weight-loss business, which remains a key growth engine.
Via StockStory · February 25, 2025

Diabetes technology company Tandem Diabetes Care (NASDAQTNDM)
will be reporting earnings tomorrow after the bell. Here’s what to expect.
Via StockStory · February 25, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · February 25, 2025

Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.
Via Chartmill · February 25, 2025

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · February 25, 2025

Via Benzinga · February 25, 2025

On the earnings call, CEO Andrew Dudum acknowledged that the transition would be "inevitable" for patients currently on compounded semaglutide.
Via Stocktwits · February 24, 2025

Hims & Hers Health Inc. (NYSEHIMS) shares dropped sharply after the company reported its fourth-quarter earnings. Here's what you need to know.
Via Benzinga · February 25, 2025

Markets fell broadly Tuesday with the S&P 500 trading at five-week lows and the Nasdaq extending its three-day losing streak. The Dow Jones managed to recover midday while Wall Street digested a weaker-than-anticipated consumer confidence survey from the Conference Board, adding to concerns over the health of the U.S.
Via Benzinga · February 25, 2025